Liver X receptor activation attenuates inflammatory response and protects cholinergic neurons in APP/PS1 transgenic mice

Neuroscience

Volumn 210, Issue , 2012, Pages 200-210

  Cui, W ^a,b   Sun, Y ^b   Wang, Z ^b,c   Xu, C ^b   Peng, Y ^b   Li, R ^b  

^a XINXIANG MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c JIUJIANG UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Cholinergic neuron; Inflammation; Liver X receptor; Nuclear factor kappaB

Indexed keywords

ABC TRANSPORTER G1; AMYLOID BETA PROTEIN[25-35]; AMYLOID PRECURSOR PROTEIN; CLUSTERIN; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; PYRROLIDINE DITHIOCARBAMATE; TRANSCRIPTION FACTOR RELA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLINERGIC NERVE CELL; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME INHIBITION; HIPPOCAMPUS; INFLAMMATION; MEYNERT BASAL NUCLEUS; MICROGLIA; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; SPATIAL MEMORY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BLOTTING, WESTERN; BRAIN; CHOLINERGIC NEURONS; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; ORPHAN NUCLEAR RECEPTORS; SIGNAL TRANSDUCTION;

EID: 84861201122     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.02.047     Document Type: Article

References (59)

1. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol Aging 2000, 21:383-421.
2. Ayasolla K., Khan M., Singh A.K., Singh I. Inflammatory mediator and beta-amyloid (25-35)-induced ceramide generation and iNOS expression are inhibited by vitamin E. Free Radic Biol Med 2004, 37:325-338.
3. Beach T.G., Kuo Y.M., Spiegel K., Emmerling M.R., Sue L.I., Kokjohn K., Roher A.E. The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer disease. J Neuropathol Exp Neurol 2000, 59:308-313.
4. Berger-Sweeney J., Stearns N.A., Murg S.L., Floerke-Nashner L.R., Lappi D.A., Baxter M.G. Selective immunolesions of cholinergic neurons in mice: effects on neuroanatomy, neurochemistry, and behavior. J Neurosci 2001, 21:8164-8173.
5. Bethea J.R., Castro M., Keane R.W., Lee T.T., Dietrich W.D., Yezierski R.P. Traumatic spinal cord injury induces nuclear factor-kappaB activation. J Neurosci 1998, 18:3251-3260.
6. Cacquevel M., Lebeurrier N., Chéenne S., Vivien D. Cytokines in neuroinflammation and Alzheimer's disease. Curr Drug Targets 2004, 5:529-534.
7. Cakala M., Malik A.R., Strosznajder J.B. Inhibitor of cyclooxygenase-2 protects against amyloid beta peptide-evoked memory impairment in mice. Pharmacol Rep 2007, 59:164-172.
8. Cao G., Bales K.R., DeMattos R.B., Paul S.M. Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics. Curr Alzheimer Res 2007, 4:179-184.
9. Casal C., Serratosa J., Tusell J.M. Effects of beta-AP peptides on activation of the transcription factor NF-kappaB and in cell proliferation in glial cell cultures. Neurosci Res 2004, 48:315-323.
10. Chen C.H., Zhou W., Liu S., Deng Y., Cai F., Tone M., Tone Y., Tong Y., Song W. Increased NF-kappaB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease. Int J Neuropsychopharmacol 2011, 1-14.
11. Chen L., Na R., Gu M., Richardson A., Ran Q. Lipid peroxidation up-regulates BACE1 expression in vivo: a possible early event of amyloidogenesis in Alzheimer's disease. J Neurochem 2008, 107:197-207.
12. Cheng O., Ostrowski R.P., Liu W., Zhang J.H. Activation of liver X receptor reduces global ischemic brain injury by reduction of nuclear factor-kappaB. Neuroscience 2010, 166:1101-1109.
13. Crisafulli C., Mazzon E., Paterniti I., Galuppo M., Bramanti P., Cuzzocrea S. Effects of Liver x receptor agonist treatment on signal transduction pathways in acute lung inflammation. Respir Res 2010, 11:19.
14. Cui W., Sun Y., Wang Z., Xu C., Xu L., Wang F., Chen Z., Peng Y., Li R. Activation of liver X receptor decreases BACE1 expression and activity by reducing membrane cholesterol levels. Neurochem Res 2011, 36:1910-1921.
15. Czech C., Burns M.P., Vardanian L., Augustin A., Jacobsen H., Baumann K., Rebeck G.W. Cholesterol independent effect of LXR agonist TO-901317 on gamma-secretase. J Neurochem 2007, 101:929-936.
16. DeKosky S.T., Ikonomovic M.D., Styren S.D., Beckett L., Wisniewski S., Bennett D.A., Cochran E.J., Kordower J.H., Mufson E.J. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002, 51:145-155.
17. Ding B.J., Ma W.W., He L.L., Zhou X., Yuan L.H., Yu H.L., Feng J.F., Xiao R. Soybean isoflavone alleviates beta-amyloid 1-42 induced inflammatory response to improve learning and memory ability by down regulation of Toll-like receptor 4 expression and nuclear factor-kappaB activity in rats. Int J Dev Neurosci 2011, 29:537-542.
18. Fitz N.F., Cronican A., Pham T., Fogg A., Fauq A.H., Chapman R., Lefterov I., Koldamova R. Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice. J Neurosci 2010, 30:6862-6872.
19. Fratiglioni L., Viitanen M., von Strauss E., Tontodonati V., Herlitz A., Winblad B. Very old women at highest risk of dementia and Alzheimer's disease: incidence data from the Kungsholmen project, Stockholm. Neurology 1997, 48:132-138.
20. Gong H., He J., Lee J.H., Mallick E., Gao X., Li S., Homanics G.E., Xie W. Activation of the liver X receptor prevents lipopolysaccharide-induced lung injury. J Biol Chem 2009, 284:30113-30121.
21. Hansen R.A., Gartlehner G., Webb A.P., Morgan L.C., Moore C.G., Jonas D.E. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging 2008, 3:211-225.
22. Jeon Y.J., Kim Y.K., Lee M., Park S.M., Han S.B., Kim H.M. Radicicol suppresses expression of inducible nitric-oxide synthase by blocking p38 kinase and nuclear factor-kappaB/Rel in lipopolysaccharide-stimulated macrophages. J Pharmacol Exp Ther 2000, 294:548-554.
23. Jiang Q., Lee C.Y., Mandrekar S., Wilkinson B., Cramer P., Zelcer N., Mann K., Lamb B., Willson T.M., Collins J.L., Richardson J.C., Smith J.D., Comery T.A., Riddell D., Holtzman D.M., Tontonoz P., Landreth G.E. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008, 58:681-693.
24. Joseph S.B., Castrillo A., Laffitte B.A., Mangelsdorf D.J., Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003, 9:213-219.
25. Koldamova R., Lefterov I. Role of LXR and ABCA1 in the pathogenesis of Alzheimer's disease-implications for a new therapeutic approach. Curr Alzheimer Res 2007, 4:171-178.
26. Koldamova R.P., Lefterov I.M., Staufenbiel M., Wolfe D., Huang S., Glorioso J.C., Walter M., Roth M.G., Lazo J.S. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem 2005, 280:4079-4088.
27. Lee J.W., Lee Y.K., Yuk D.Y., Choi D.Y., Ban S.B., Oh K.W., Hong J.T. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J Neuroinflammation 2008, 5:37.
28. Lefterov I., Bookout A., Wang Z., Staufenbiel M., Mangelsdorf D., Koldamova R. Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment. Mol Neurodegener 2007, 2:20.
29. Liang Y., Lin S., Beyer T.P., Zhang Y., Wu X., Bales K.R., DeMattos R.B., May P.C., Li S.D., Jiang X.C., Eacho P.I., Cao G., Paul S.M. A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. J Neurochem 2004, 88:623-634.
30. McKinney M., Jacksonville M.C. Brain cholinergic vulnerability: relevance to behavior and disease. Biochem Pharmacol 2005, 70:1115-1124.
31. Melo J.B., Agostinho P., Oliveira C.R. Involvement of oxidative stress in the enhancement of acetylcholinesterase activity induced by amyloid beta-peptide. Neurosci Res 2003, 45:117-127.
32. Minkeviciene R., Ihalainen J., Malm T., Matilainen O., Keksa-Goldsteine V., Goldsteins G., Iivonen H., Leguit N., Glennon J., Koistinaho J., Banerjee P., Tanila H. Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. J Neurochem 2008, 105:584-594.
33. Morales J.R., Ballesteros I., Deniz J.M., Hurtado O., Vivancos J., Nombela F., Lizasoain I., Castrillo A., Moro M.A. Activation of liver X receptors promotes neuroprotection and reduces brain inflammation in experimental stroke. Circulation 2008, 118:1450-1459.
34. Morihara T., Teter B., Yang F., Lim G.P., Boudinot S., Boudinot F.D., Frautschy S.A., Cole G.M. Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models. Neuropsychopharmacology 2005, 30:1111-1120.
35. Mufson E.J., Ginsberg S.D., Ikonomovic M.D., DeKosky S.T. Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J Chem Neuroanat 2003, 26:233-242.
36. Mufson E.J., Ma S.Y., Dills J., Cochran E.J., Leurgans S., Wuu J., Bennett D.A., Jaffar S., Gilmor M.L., Levey A.I., Kordower J.H. Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol 2002, 443:136-153.
37. O'Banion M.K. COX-2 and Alzheimer's disease: potential roles in inflammation and neurodegeneration. Expert Opin Invest Drugs 1999, 8:1521-1536.
38. Ock J., Kim S., Yi K.Y., Kim N.J., Han H.S., Cho J.Y., Suk K. A novel anti-neuroinflammatory pyridylimidazole compound KR-31360. Biochem Pharmacol 2010, 79:596-609.
39. Paterniti I., Genovese T., Mazzon E., Crisafulli C., Di Paola R., Galuppo M., Bramanti P., Cuzzocrea S. Liver X receptor agonist treatment regulates inflammatory response after spinal cord trauma. J Neurochem 2010, 112:611-624.
40. Perez J.L., Carrero I., Gonzalo P., Arevalo-Serrano J., Sanz-Anquela J.M., Ortega J., Rodriguez M., Gonzalo-Ruiz A. Soluble oligomeric forms of beta-amyloid (Abeta) peptide stimulate Abeta production via astrogliosis in the rat brain. Exp Neurol 2010, 223:410-421.
41. Perez S.E., He B., Muhammad N., Oh K.J., Fahnestock M., Ikonomovic M., Mufson E.J. Cholinotrophic basal forebrain system alterations in 3xTg-AD transgenic mice. Neurobiol Dis 2011, 41:338-352.
42. Quadros A., Patel N., Crescentini R., Crawford F., Paris D., Mullan M. Increased TNFalpha production and Cox-2 activity in organotypic brain slice cultures from APPsw transgenic mice. Neurosci Lett 2003, 353:66-68.
43. Repa J.J., Turley S.D., Lobaccaro J.A., Medina J., Li L., Lustig K., Shan B., Heyman R.A., Dietschy J.M., Mangelsdorf D.J. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000, 289:1524-1529.
44. Riddell D.R., Christie G., Hussain I., Dingwall C. Compartmentalization of beta-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts. Curr Biol 2001, 11:1288-1293.
45. Riddell D.R., Zhou H., Comery T.A., Kouranova E., Lo C.F., Warwick H.K., Ring R.H., Kirksey Y., Aschmies S., Xu J., Kubek K., Hirst W.D., Gonzales C., Chen Y., Murphy E., Leonard S., Vasylyev D., Oganesian A., Martone R.L., Pangalos M.N., Reinhart P.H., Jacobsen J.S. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci 2007, 34:621-628.
46. Rodrigo J., Fernández-Vizarra P., Castro-Blanco S., Bentura M.L., Nieto M., Gómez-Isla T., Martínez-Murillo R., MartInez A., Serrano J., Fernández A.P. Nitric oxide in the cerebral cortex of amyloid-precursor protein (SW) Tg2576 transgenic mice. Neuroscience 2004, 128:73-89.
47. Saura J., Tusell J.M., Serratosa J. High-yield isolation of murine microglia by mild trypsinization. Glia 2003, 44:183-189.
48. Schafer S., Wirths O., Multhaup G., Bayer T.A. Gender dependent APP processing in a transgenic mouse model of Alzheimer's disease. J Neural Transm 2007, 114:387-394.
49. Schwab C., McGeer P.L. Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. J Alzheimers Dis 2008, 13:359-369.
50. Sironi L., Mitro N., Cimino M., Gelosa P., Guerrini U., Tremoli E., Saez E. Treatment with LXR agonists after focal cerebral ischemia prevents brain damage. FEBS Lett 2008, 582:3396-3400.
51. Sun Y., Yao J., Kim T.W., Tall A.R. Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. J Biol Chem 2003, 278:27688-27694.
52. Tyagi E., Agrawal R., Nath C., Shukla R. Cholinergic protection via alpha7 nicotinic acetylcholine receptors and PI3K-Akt pathway in LPS-induced neuroinflammation. Neurochem Int 2010, 56:135-142.
53. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M.A., Biere A.L., Curran E., Burgess T., Louis J.C., Collins F., Treanor J., Rogers G., Citron M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741.
54. Wang F., Chen H., Sun X. Age-related spatial cognitive impairment is correlated with a decrease in ChAT in the cerebral cortex, hippocampus and forebrain of SAMP8 mice. Neurosci Lett 2009, 454:212-217.
55. Whitney K.D., Watson M.A., Collins J.L., Benson W.G., Stone T.M., Numerick M.J., Tippin T.K., Wilson J.G., Winegar D.A., Kliewer S.A. Regulation of cholesterol homeostasis by the liver X receptors in the central nervous system. Mol Endocrinol 2002, 16:1378-1385.
56. Wyss-Coray T., Mucke L. Inflammation in neurodegenerative disease-a double-edged sword. Neuron 2002, 35:419-432.
57. Yamamoto Y., Gaynor R.B. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001, 107:135-142.
58. Yan Q., Zhang J., Liu H., Babu-Khan S., Vassar R., Biere A.L., Citron M., Landreth G. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 2003, 23:7504-7509.
59. Zelcer N., Khanlou N., Clare R., Jiang Q., Reed-Geaghan E.G., Landreth G.E., Vinters H.V., Tontonoz P. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc Natl Acad Sci U S A 2007, 104:10601-10606.